Protective Association of Klotho Rs495392 Gene Polymorphism Against Hepatic Steatosis in Non-alcoholic Fatty Liver Disease Patients

Overview

Journal Clin Mol Hepatol

Specialty Gastroenterology

Date 2021 Nov 29

PMID 34839623

Citations 4

Authors

Wen-Yue Liu

Xiaofang Zhang

Gang Li

Liang-Jie Tang

Pei-Wu Zhu

Rafael S Rios

Kenneth I Zheng

Hong-Lei Ma

Xiao-Dong Wang

Qiuwei Pan

Robert J de Knegt

Luca Valenti

Mohsen Ghanbari

Ming-Hua Zheng

Affiliations

Soon will be listed here.

Abstract

Background/aims: Non-alcoholic fatty liver disease (NAFLD) is closely associated with metabolic dysfunction. Among the multiple factors, genetic variation acts as important modifiers. Klotho, an enzyme encoded by the klotho (KL) gene in human, has been implicated in the pathogenesis of metabolic dysfunctions. However, the impact of variants in KL on NAFLD risk remains poorly understood. The aim of this study was to investigate the impact of KL rs495392 C>A polymorphism on the histological severity of NAFLD.

Methods: We evaluated the impact of the KL rs495392 polymorphism on liver histology in 531 Chinese with NAFLD and replicated that in the population-based Rotterdam Study cohort. The interactions between the rs495392, vitamin D, and patatin-like phospholipase domain containing 3 (PNPLA3) rs738409 polymorphism were also analyzed.

Results: Carriage of the rs495392 A allele had a protective effect on steatosis severity (odds ratio [OR], 0.61; 95% confidence interval [CI], 0.42-0.89; P=0.010) in Chinese patients. After adjustment for potential confounders, the A allele remained significant with a protective effect (OR, 0.66; 95% CI, 0.45-0.98; P=0.040). The effect on hepatic steatosis was confirmed in the Rotterdam Study cohort. Additional analysis showed the association between serum vitamin D levels and NAFLD specifically in rs495392 A allele carriers, but not in non-carriers. Moreover, we found that the rs495392 A allele attenuated the detrimental impact of PNPLA3 rs738409 G allele on the risk of severe hepatic steatosis.

Conclusion: The KL rs495392 polymorphism has a protective effect against hepatic steatosis in patients with NAFLD.

Citing Articles

The relationship of serum klotho levels and triglyceride glucose index-related indicators.

Zhou Y, Wang Y, Li F, Shi Y, Wu T, Li Y Lipids Health Dis. 2024; 23(1):399.

PMID: 39639327 PMC: 11619470. DOI: 10.1186/s12944-024-02379-4.

Advances in genetic variation in metabolism-related fatty liver disease.

Shi F, Zhao M, Zheng S, Zheng L, Wang H Front Genet. 2023; 14:1213916.

PMID: 37753315 PMC: 10518415. DOI: 10.3389/fgene.2023.1213916.

CSAD Ameliorates Lipid Accumulation in High-Fat Diet-Fed Mice.

Tan R, Li J, Liu L, Wu Q, Fan L, Ma N Int J Mol Sci. 2022; 23(24).

PMID: 36555571 PMC: 9783087. DOI: 10.3390/ijms232415931.

Klotho Levels and Their Relationship with Inflammation and Survival among Alcoholic Patients.

Martin-Gonzalez C, Espelosin-Ortega E, Abreu-Gonzalez P, Fernandez-Rodriguez C, Vera-Delgado V, Gonzalez-Navarrete L Biomolecules. 2022; 12(8).

PMID: 36009045 PMC: 9405938. DOI: 10.3390/biom12081151.

References

Cho Y, Kim J, Shim J, Yang H, Chang J, Moon J . Association Between Vitamin D Deficiency and Suspected Nonalcoholic Fatty Liver Disease in an Adolescent Population. Pediatr Gastroenterol Hepatol Nutr. 2019; 22(3):233-241. PMC: 6506433. DOI: 10.5223/pghn.2019.22.3.233. View

Kuro-O M . The Klotho proteins in health and disease. Nat Rev Nephrol. 2018; 15(1):27-44. DOI: 10.1038/s41581-018-0078-3. View

Petta S, Maida M, Macaluso F, Di Marco V, Camma C, Cabibi D . The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease. Hepatology. 2015; 62(4):1101-10. DOI: 10.1002/hep.27844. View

Gu H, Jiang W, You N, Huang X, Li Y, Peng X . Soluble Klotho Improves Hepatic Glucose and Lipid Homeostasis in Type 2 Diabetes. Mol Ther Methods Clin Dev. 2020; 18:811-823. PMC: 7479259. DOI: 10.1016/j.omtm.2020.08.002. View

Liu W, Zheng K, Pan X, Ma H, Zhu P, Wu X . Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2019; 35(6):1057-1064. DOI: 10.1111/jgh.14894. View

Rao U, Engelhardt B . Predicting Immuno-Metabolic Complications After Allogeneic Hematopoietic Cell Transplant with the Cytokine Interleukin-33 (IL-33) and its Receptor Serum-Stimulation 2 (ST2). Clin Hematol Int. 2021; 2(3):101-108. PMC: 8432328. DOI: 10.2991/chi.d.200506.002. View

Brunt E, W-S Wong V, Nobili V, Day C, Sookoian S, Maher J . Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2016; 1:15080. DOI: 10.1038/nrdp.2015.80. View

Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T . Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997; 390(6655):45-51. DOI: 10.1038/36285. View

Saberi B, Dadabhai A, Nanavati J, Wang L, Shinohara R, Mullin G . Vitamin D levels do not predict the stage of hepatic fibrosis in patients with non-alcoholic fatty liver disease: A PRISMA compliant systematic review and meta-analysis of pooled data. World J Hepatol. 2018; 10(1):142-154. PMC: 5787678. DOI: 10.4254/wjh.v10.i1.142. View

10.

Jaruvongvanich V, Ahuja W, Sanguankeo A, Wijarnpreecha K, Upala S . Vitamin D and histologic severity of nonalcoholic fatty liver disease: A systematic review and meta-analysis. Dig Liver Dis. 2017; 49(6):618-622. DOI: 10.1016/j.dld.2017.02.003. View

11.

He X, Shen Y, Ma X, Ying L, Peng J, Pan X . The association of serum FGF23 and non-alcoholic fatty liver disease is independent of vitamin D in type 2 diabetes patients. Clin Exp Pharmacol Physiol. 2018; 45(7):668-674. DOI: 10.1111/1440-1681.12933. View

12.

Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G . Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2006; 17(7):517-24. DOI: 10.1016/j.numecd.2006.04.002. View

13.

Watt M, Miotto P, De Nardo W, Montgomery M . The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance. Endocr Rev. 2019; 40(5):1367-1393. DOI: 10.1210/er.2019-00034. View

14.

Amitani M, Asakawa A, Amitani H, Kaimoto K, Sameshima N, Koyama K . Plasma klotho levels decrease in both anorexia nervosa and obesity. Nutrition. 2013; 29(9):1106-9. DOI: 10.1016/j.nut.2013.02.005. View

15.

Pacifico L, Osborn J, Bonci E, Pierimarchi P, Chiesa C . Association between Vitamin D Levels and Nonalcoholic Fatty Liver Disease: Potential Confounding Variables. Mini Rev Med Chem. 2018; 19(4):310-332. DOI: 10.2174/1389557518666181025153712. View

16.

Nie F, Wu D, Du H, Yang X, Yang M, Pang X . Serum klotho protein levels and their correlations with the progression of type 2 diabetes mellitus. J Diabetes Complications. 2016; 31(3):594-598. DOI: 10.1016/j.jdiacomp.2016.11.008. View

17.

Westra H, Peters M, Esko T, Yaghootkar H, Schurmann C, Kettunen J . Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat Genet. 2013; 45(10):1238-1243. PMC: 3991562. DOI: 10.1038/ng.2756. View

18.

Lee I, Park E, Cho J . Association of nonalcoholic fatty liver disease with serum vitamin D levels in combination of physical fitness in korean older adults. J Steroid Biochem Mol Biol. 2020; 198:105569. DOI: 10.1016/j.jsbmb.2019.105569. View

19.

Kim Y, Kim J, Nam Y, Kong M, Kim Y, Yu K . Klotho is a genetic risk factor for ischemic stroke caused by cardioembolism in Korean females. Neurosci Lett. 2006; 407(3):189-94. DOI: 10.1016/j.neulet.2006.08.039. View

20.

Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View